about
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myelomaHedgehog signaling: modulation of cancer properies and tumor mircroenvironmentAssociation of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancerStatins and cancersTargeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapyAnti-cancer vaccines - a one-hit wonder?γδ T cells for cancer immunotherapy: A systematic review of clinical trialsCheckpoint modulation--A new way to direct the immune system against renal cell carcinomaDistinct effects of IL-18 on the engraftment and function of human effector CD8 T cells and regulatory T cellsRegulatory T Cell Modulation by CBP/EP300 Bromodomain InhibitionImmunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?Mitigating age-related immune dysfunction heightens the efficacy of tumor immunotherapy in aged mice.Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy.Modulators of arginine metabolism support cancer immunosurveillance.Blocking TLR2 activity attenuates pulmonary metastases of tumor.Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer modelTargeting a mimotope vaccine to activating Fcgamma receptors empowers dendritic cells to prime specific CD8+ T cell responses in tumor-bearing mice.Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer.Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival.Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancerSpontaneous regression of metastatic cancer cells in the lymph node: a case reportThe role of regulatory T cells in cancer.CCL2 blockade augments cancer immunotherapy.Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells.DNA vaccines: developing new strategies against cancer.Disruption of TGF-beta signaling prevents the generation of tumor-sensitized regulatory T cells and facilitates therapeutic antitumor immunity.MiR21 sensitized B-lymphoma cells to ABT-199 via ICOS/ICOSL-mediated interaction of Treg cells with endothelial cellsCD8+ Tregs in lupus, autoimmunity, and beyond.Elevated levels of select gangliosides in T cells from renal cell carcinoma patients is associated with T cell dysfunction.Targeting inhibitory pathways in cancer immunotherapy.Fully human antagonistic antibodies against CCR4 potently inhibit cell signaling and chemotaxis.Timing is critical for an effective anti-metastatic immunotherapy: the decisive role of IFNγ/STAT1-mediated activation of autophagyEnhancement of electroporation facilitated immunogene therapy via T-reg depletion.Tumor microenvironment and immune effects of antineoplastic therapy in lymphoproliferative syndromes.Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma.Curcumin reverses T cell-mediated adaptive immune dysfunctions in tumor-bearing hostsAnti-HER2 vaccines: new prospects for breast cancer therapyExpression and DNA methylation of TNF, IFNG and FOXP3 in colorectal cancer and their prognostic significance.Human regulatory T cells in autoimmune diseasesExpansion of regulatory GITR+CD25 low/-CD4+ T cells in systemic lupus erythematosus patients.
P2860
Q24605861-94F88905-55C2-4EBA-AEE8-7ED39390762CQ26764740-52CC7544-6EE7-4121-A5D6-0EEDE14A2A2AQ26774690-4B48D00F-411A-42FA-9E4C-8E8C68EDC34CQ26777793-8741B74D-3508-4F91-BD85-6EFDB700AFC0Q26991589-E980D7C6-202F-4822-8C83-87DA3699155DQ26995164-DC47F13A-11E9-443B-8513-4B635A00C497Q27021705-50021981-5016-4CBE-95A1-2044C1D5EDA2Q27025873-A8CEC00D-1C7C-4310-B25C-B397D6A1F32FQ27438176-036C1434-F99B-460F-A986-04463CA931FBQ27644651-E05DC1C3-DD37-41AF-B95E-A12F08300E23Q28301672-AA3A57D8-DCDB-4CED-88DD-A2339EDD141FQ30513468-A3FF1DE7-6CE4-4774-B898-4C6005EDDF2FQ33311571-F1C8BD54-0EBD-429E-AF6E-2F4E0DC88017Q33398779-756FB7DB-3DF6-4C6C-8B09-65647F8DB122Q33490618-67A8B981-F7DC-4F7E-86AA-D002169B1065Q33517133-E30B75F8-AE1B-4CE9-9903-18D7888BA7C4Q33584637-C245FE01-BF65-48E5-8671-3A408D990167Q33584851-7DBD0B10-3B10-42F0-B1B2-376CF94D3DDBQ33584997-857A8D87-19B9-4154-B288-94FD0C0E6467Q33608626-F7526A19-F7E9-48CB-B2C7-12FB82435F9EQ33629800-9C975EEC-A716-4D13-866B-32D439239E19Q33631986-D5FC50CF-6F94-449D-83F9-C80929A3A3E7Q33651427-61BDFA21-0CEC-4015-8467-FBBFD937E105Q33748026-8CF355F9-AF4E-4B39-8271-211FF9C7AC86Q33756622-19A37FF0-CF97-4605-89DA-7C621CCE53FCQ33772507-847C2778-A9D0-4A61-94E0-66E81C51BBE5Q33823801-237FDE09-377B-4448-8A1F-E4B168134D66Q33889097-E6F984DB-FFC1-4D4E-B90F-DC4D7B8C5447Q33932479-DCB73366-093E-4121-9688-8C252D95442BQ33950640-BA09AD29-8F3D-4C47-A232-35C6A2DB0EF0Q33982582-DBD1BFD2-95B3-4871-BFFC-8DF1279B3D6FQ34023964-3AD5453E-1699-4B27-AC9F-A37716202775Q34072036-7160EBE5-B8A3-43CE-BE4D-9735BFA6A2D9Q34097414-83A65199-3906-489D-BCAE-4742CA52540EQ34099760-A24304FA-561E-42D9-886D-B1702B89EB31Q34105756-E397A3A3-5DD1-4B06-BEA9-8428E6530B1FQ34105959-403D95AA-AECF-4114-877B-A45F6FDB9093Q34354653-41EF6B41-5420-44C4-9D74-4BB454BA44C1Q34384366-776A0916-46BE-4CB1-A21D-ABFEF53BE546Q34401977-C3FDD01B-38C7-49F2-A2D5-A289D7983163
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Tregs and rethinking cancer immunotherapy.
@ast
Tregs and rethinking cancer immunotherapy.
@en
Tregs and rethinking cancer immunotherapy.
@nl
type
label
Tregs and rethinking cancer immunotherapy.
@ast
Tregs and rethinking cancer immunotherapy.
@en
Tregs and rethinking cancer immunotherapy.
@nl
prefLabel
Tregs and rethinking cancer immunotherapy.
@ast
Tregs and rethinking cancer immunotherapy.
@en
Tregs and rethinking cancer immunotherapy.
@nl
P2860
P356
P1476
Tregs and rethinking cancer immunotherapy.
@en
P2093
Tyler J Curiel
P2860
P304
P356
10.1172/JCI31202
P407
P577
2007-05-01T00:00:00Z